MapLight Therapeutics, Inc. (MPLT) earnings date
Mar 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 47 days, typically, give or take 18 (last 5 releases) |
Last 5 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 16, 2026 | before open | 47 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | after close | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | after close | 44 | 8-K |
| Q4 FY2025 | Thu, Mar 26, 2026 | before open | 85 | 8-K |
| Q3 FY2025 | Thu, Dec 4, 2025 | before open | 65 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results now expected in 2028; ML-007C-MA holds FDA Fast Track designation in ADP Ended the quarter with $463.4 million in cash, cash equivalents and investments, expected to fund operations through key clinical readouts and through 2028 SAN F" exhibit |
| Q3 FY2026 | "With our cash position expected to fund operations through 2028, we are well-positioned to advance both programs while maintaining strategic and financial flexibility.”" exhibit |
| Q3 FY2026 | "The Company has initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial, and intends to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, with topline results expected in 2028." exhibit |
| Q3 FY2026 | "Topline results from VISTA are expected in the second half of 2027." exhibit |
| Q3 FY2026 | "Based on current operational plans and assumptions, the Company expects that its existing cash, cash equivalents and investments will be sufficient to fund the continued advancement of ML-007C-MA through 2028." exhibit |
| Q2 FY2026 | "Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027 Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup Primarily focusing resources on the advancement of ML-007C-MA" exhibit |
| Q2 FY2026 | "Ended the quarter with $351.3 million in cash, cash equivalents and investments, which, together with the Company’s recent $150 million private placement, is expected to extend cash runway through 2028, including through the projected readouts for both VISTA and ZEPHYR-2" exhibit |
| Q2 FY2026 | "In ADP, enrollment in VISTA remains ongoing, with topline results expected in the second half of 2027." exhibit |
| Q2 FY2026 | "The Company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path forward, including the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028." exhibit |
| Q2 FY2026 | "Topline results from VISTA are expected in the second half of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MPLT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MPLT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MPLT/"><img src="https://veritasdata.dev/embed/MPLT.svg" alt="MPLT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MPLT/)
Script
<script async src="https://veritasdata.dev/embed/MPLT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MPLT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.